Keytruda

News

BMS bags a double-quick colorectal cancer approval from FDA

The FDA has approved Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for patients with a particular form of colorectal cancer.

News

MSD says subcutaneous Keytruda matches IV form

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial.

News

Can Keytruda finally break into early head and neck cancer?

The FDA is set to decide on MSD's Keytruda as perioperative treatment of locally advanced head and neck squamous cell carcinoma in June.

News

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.

News

MSD gets first positive trial of Keytruda/Lynparza combo

After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.

News

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

BMS bags a double-quick colorectal cancer approval from FDA

MSD says subcutaneous Keytruda matches IV form

Can Keytruda finally break into early head and neck cancer?

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

MSD gets first positive trial of Keytruda/Lynparza combo

MSD says subcutaneous Keytruda matches IV form

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Keytruda

Editor's Picks